# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 ...
Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promisi...
Guggenheim analyst Kelsey Goodwin maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $99 to $105.
Wedbush analyst David Nierengarten maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $99 t...
BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $102 to...
Stifel analyst Bradley Canino maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $115 to $135.